Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from EXACT Therapeutics AS ( (DE:56F) ) is now available.
EXACT Therapeutics has corrected a previous stock exchange announcement regarding the exercise period for its remaining warrants, clarifying that the final date for warrant holders to exercise their rights is 26 February 2026, not 21 February 2026 as initially stated. The clarification removes potential confusion for investors and ensures warrant holders have accurate information on the exercise window, which may influence short-term trading dynamics and capital structure planning for the company.
More about EXACT Therapeutics AS
EXACT Therapeutics AS is a clinical-stage precision medicine company that uses ultrasound technology to activate its proprietary drug candidate PS101, with the aim of enhancing the clinical benefit of oncology treatments. PS101 has a unique mechanism of action and is designed to be combined with a broad range of therapeutic agents in cancer and potentially other indications, including brain diseases. The company is listed on Euronext Growth Oslo under the ticker EXTX.
Average Trading Volume: 41,242
Current Market Cap: NOK120.2M
Learn more about 56F stock on TipRanks’ Stock Analysis page.